Description of Research Expertise

My research focuses on inflammatory bowel disease specifically Crohn's disease and Ulcerative Colitis. My particular focuses include
1.) medical therapy of inflammatory bowel disease,
2.) safety of current medical therapy for IBD, and
3.) natural history of disease

Selected Publications

Armuzzi A, Cross RK, Lichtenstein GR, Hou J, Deepak P, Regueiro M, Wolfm DC, Akukwe L, Ahmad HA, Jain A, Kozinn M, Wu H, Petersen AK, Charles L, Long M.: Cardiovascular Safety of Ozanimod in Patients With Ulcerative Colitis: True North and Open-Label Extension Analyses Clincial Gastroenterology and Hepatology : 2023.

Lichtenstein GR.: Virtual Reality and Disorders of Gut-Brain Interaction. Gastroenterol Hepatol (N Y). : 2023.

Weber A. and Lichtenstein GR.: Evidence-Based Approach to Chronic Antibody-Refractory Pouchitis (CARP): A Review. Disease of the Colon and Rectum : 2023.

Gary R. Lichtenstein, Scott D. Lee, Brian G. Feagan, Edward V. Loftus, Samson Ng, Kaitlin Dehlin, and others.: PREGNANCY OUTCOMES IN CROHN'S DISEASE PATIENTS EXPOSED TO CERTOLIZUMAB PEGOL: SAFETY DATA FROM THE SECURE REGISTRY Gastroenterology : 2023.

Remo Panaccione, Gary Roth Lichtenstein, Hiroshi Nakase, Alessandro Armuzzi, Torsten Kucharzik, Gweneth Levy, Hannah Palac, Michelle Kujawski, Justin klaff, Jae Hee Cheon: SAFETY OF UPADACITINIB IN ULCERATIVE COLITIS: LONG-TERM DATA FROM THE PHASE 3 OPEN-LABEL EXTENSION STUDY (U-ACTIVATE) Gastroenterology : 2023.

Khan, R.M.Q, Schwartz, D.A, Sands, B.E, Hanauer, S, Uddin, S, Mukherjee, R, Lichtenstein, G.: Clinical trial design in Crohn’s disease: interpreting future endpoints based on post hoc analyses of the vedolizumab phase 3 trials GEMINI 2 and VISIBLE 2. Journal of Crohn’s and Colitis : 2023.

Bhattacharya A, Travis D, Osterman MT, Lewis JD, Bhagya Rao B, Lee H, Lichtenstein GR.: Supratherapeutic Infliximab Levels Do Not Predict Risk of Short-term Complications in Adults With Crohn's Disease. J Clin Gastroenterol. : 2023.

Lichtenstein GR.: Liver Transplant in Patients With Obesity. Gastroenterol Hepatol (N Y). : 2023.

Mukherjee, Qasim Rana Khan, Julia J. Liu, Ashwin Ananthakrishnan, Gary Roth Lichtenstein, Sharif M. Uddin, Lisa Young, Mena Boules, Paula Adamson, Vonda Reeves Richa Sagar: EFFICACY AND SAFETY OUTCOMES IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS STRATIFIED BY ETHNICITY AND RACE: A POOLED ANALYSIS OF DATA FROM GEMINI 1, VARSITY, AND VISIBLE 1. Gastroenterology : 2023.

Peyrin-Biroulet L, Allegretti JR, Rubin DT, Bressler B, Germinano M, Huang K-H, SHipitofsky N, Zhang H, Wilson, R, Han C, Feagan BG, Sandborn WJ, Panes J, Hisamatsu T, Lichtenstein GR, Sands BE and Dignass A.: Guselkumab In Patients with Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study. Gastroenterology : 2023.

View all publications

Academic Contact Information

3400 Civic Center Boulevard
753 Perelman Center for Advanced Medicine
South Pavilion
Philadelphia, PA 19104
Phone: 215-349-8222
Patient appointments: 800-789-7366